CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $260,766 | -18.6% | 5,745 | +0.7% | 0.00% | -33.3% |
| Q2 2023 | $320,391 | -13.9% | 5,707 | -30.6% | 0.00% | 0.0% |
| Q1 2023 | $372,030 | +6.4% | 8,226 | -4.3% | 0.00% | 0.0% |
| Q4 2022 | $349,590 | -19.4% | 8,600 | +29.5% | 0.00% | -66.7% |
| Q3 2022 | $434,000 | -11.4% | 6,643 | -17.6% | 0.01% | +12.5% |
| Q2 2022 | $490,000 | -0.2% | 8,064 | +3.0% | 0.01% | +14.3% |
| Q1 2022 | $491,000 | -7.0% | 7,827 | +12.4% | 0.01% | -12.5% |
| Q4 2021 | $528,000 | -34.7% | 6,964 | -3.5% | 0.01% | -38.5% |
| Q3 2021 | $808,000 | -22.1% | 7,217 | +12.6% | 0.01% | -23.5% |
| Q2 2021 | $1,037,000 | +84.2% | 6,408 | +38.6% | 0.02% | +54.5% |
| Q1 2021 | $563,000 | -28.1% | 4,622 | -9.6% | 0.01% | -26.7% |
| Q4 2020 | $783,000 | – | 5,111 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |